90 related articles for article (PubMed ID: 37391098)
1. Covalent adduction of serotonin-derived quinones to the SARS-CoV-2 main protease expressed in a cultured cell.
Kato Y; Sakanishi A; Matsuda K; Hattori M; Kaneko I; Nishikawa M; Ikushiro S
Free Radic Biol Med; 2023 Sep; 206():74-82. PubMed ID: 37391098
[TBL] [Abstract][Full Text] [Related]
2. Food phytochemicals, epigallocatechin gallate and myricetin, covalently bind to the active site of the coronavirus main protease
Kato Y; Higashiyama A; Takaoka E; Nishikawa M; Ikushiro S
Adv Redox Res; 2021 Dec; 3():100021. PubMed ID: 35425933
[TBL] [Abstract][Full Text] [Related]
3. A Critical Study on Acylating and Covalent Reversible Fragment Inhibitors of SARS-CoV-2 Main Protease Targeting the S1 Site with Pyridine.
Wamser R; Pach S; Arkona C; Baumgardt M; Aziz UBA; Hocke AC; Wolber G; Rademann J
ChemMedChem; 2023 May; 18(9):e202200635. PubMed ID: 36812048
[TBL] [Abstract][Full Text] [Related]
4. Discovery of novel SARS-CoV-2 3CL protease covalent inhibitors using deep learning-based screen.
Wang L; Yu Z; Wang S; Guo Z; Sun Q; Lai L
Eur J Med Chem; 2022 Dec; 244():114803. PubMed ID: 36209629
[TBL] [Abstract][Full Text] [Related]
5. Targeting SARS-CoV-2 viral proteases as a therapeutic strategy to treat COVID-19.
Anirudhan V; Lee H; Cheng H; Cooper L; Rong L
J Med Virol; 2021 May; 93(5):2722-2734. PubMed ID: 33475167
[TBL] [Abstract][Full Text] [Related]
6. A multi-pronged evaluation of aldehyde-based tripeptidyl main protease inhibitors as SARS-CoV-2 antivirals.
Ma Y; Yang KS; Geng ZZ; Alugubelli YR; Shaabani N; Vatansever EC; Ma XR; Cho CC; Khatua K; Xiao J; Blankenship LR; Yu G; Sankaran B; Li P; Allen R; Ji H; Xu S; Liu WR
Eur J Med Chem; 2022 Oct; 240():114570. PubMed ID: 35779291
[TBL] [Abstract][Full Text] [Related]
7. Discovery of SARS-CoV-2 main protease covalent inhibitors from a DNA-encoded library selection.
Ge R; Shen Z; Yin J; Chen W; Zhang Q; An Y; Tang D; Satz AL; Su W; Kuai L
SLAS Discov; 2022 Mar; 27(2):79-85. PubMed ID: 35063690
[TBL] [Abstract][Full Text] [Related]
8. Identification of Aloe-derived natural products as prospective lead scaffolds for SARS-CoV-2 main protease (M
Hicks EG; Kandel SE; Lampe JN
Bioorg Med Chem Lett; 2022 Jun; 66():128732. PubMed ID: 35427739
[TBL] [Abstract][Full Text] [Related]
9. Broad-spectrum coronavirus 3C-like protease peptidomimetic inhibitors effectively block SARS-CoV-2 replication in cells: Design, synthesis, biological evaluation, and X-ray structure determination.
Stefanelli I; Corona A; Cerchia C; Cassese E; Improta S; Costanzi E; Pelliccia S; Morasso S; Esposito F; Paulis A; Scognamiglio S; Di Leva FS; Storici P; Brindisi M; Tramontano E; Cannalire R; Summa V
Eur J Med Chem; 2023 May; 253():115311. PubMed ID: 37043904
[TBL] [Abstract][Full Text] [Related]
10. A Quick Route to Multiple Highly Potent SARS-CoV-2 Main Protease Inhibitors*.
Yang KS; Ma XR; Ma Y; Alugubelli YR; Scott DA; Vatansever EC; Drelich AK; Sankaran B; Geng ZZ; Blankenship LR; Ward HE; Sheng YJ; Hsu JC; Kratch KC; Zhao B; Hayatshahi HS; Liu J; Li P; Fierke CA; Tseng CK; Xu S; Liu WR
ChemMedChem; 2021 Mar; 16(6):942-948. PubMed ID: 33283984
[TBL] [Abstract][Full Text] [Related]
11. Estimating the binding energetics of reversible covalent inhibitors of the SARS-CoV-2 main protease: an
Awoonor-Williams E
Phys Chem Chem Phys; 2022 Oct; 24(38):23391-23401. PubMed ID: 36128834
[TBL] [Abstract][Full Text] [Related]
12. Production of a functionally active recombinant SARS-CoV-2 (COVID-19) 3C-like protease and a soluble inactive 3C-like protease-RBD chimeric in a prokaryotic expression system.
De Marco Verissimo C; López Corrales J; Dorey AL; Cwiklinski K; Lalor R; Calvani NED; Jewhurst HL; Flaus A; Doyle S; Dalton JP
Epidemiol Infect; 2022 Jun; 150():e128. PubMed ID: 35723031
[TBL] [Abstract][Full Text] [Related]
13. Small-Molecule Thioesters as SARS-CoV-2 Main Protease Inhibitors: Enzyme Inhibition, Structure-Activity Relationships, Antiviral Activity, and X-ray Structure Determination.
Pillaiyar T; Flury P; Krüger N; Su H; Schäkel L; Barbosa Da Silva E; Eppler O; Kronenberger T; Nie T; Luedtke S; Rocha C; Sylvester K; Petry MRI; McKerrow JH; Poso A; Pöhlmann S; Gütschow M; O'Donoghue AJ; Xu Y; Müller CE; Laufer SA
J Med Chem; 2022 Jul; 65(13):9376-9395. PubMed ID: 35709506
[TBL] [Abstract][Full Text] [Related]
14. Discovery of M Protease Inhibitors Encoded by SARS-CoV-2.
Hung HC; Ke YY; Huang SY; Huang PN; Kung YA; Chang TY; Yen KJ; Peng TT; Chang SE; Huang CT; Tsai YR; Wu SH; Lee SJ; Lin JH; Liu BS; Sung WC; Shih SR; Chen CT; Hsu JT
Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32669265
[TBL] [Abstract][Full Text] [Related]
15. An integrated metabolomic and proteomic approach for the identification of covalent inhibitors of the main protease (M
Baron G; Borella S; Della Vedova L; Vittorio S; Vistoli G; Carini M; Aldini G; Altomare A
Talanta; 2023 Jan; 252():123824. PubMed ID: 36027618
[TBL] [Abstract][Full Text] [Related]
16. Potential inhibitors of the main protease of SARS-CoV-2 and modulators of arachidonic acid pathway: Non-steroidal anti-inflammatory drugs against COVID-19.
Sisakht M; Solhjoo A; Mahmoodzadeh A; Fathalipour M; Kabiri M; Sakhteman A
Comput Biol Med; 2021 Sep; 136():104686. PubMed ID: 34340125
[TBL] [Abstract][Full Text] [Related]
17. In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing.
Kumar Y; Singh H; Patel CN
J Infect Public Health; 2020 Sep; 13(9):1210-1223. PubMed ID: 32561274
[TBL] [Abstract][Full Text] [Related]
18. Repurposing of renin inhibitors as SARS-COV-2 main protease inhibitors: A computational study.
Refaey RH; El-Ashrey MK; Nissan YM
Virology; 2021 Feb; 554():48-54. PubMed ID: 33370597
[TBL] [Abstract][Full Text] [Related]
19. 3C-like protease inhibitors block coronavirus replication in vitro and improve survival in MERS-CoV-infected mice.
Rathnayake AD; Zheng J; Kim Y; Perera KD; Mackin S; Meyerholz DK; Kashipathy MM; Battaile KP; Lovell S; Perlman S; Groutas WC; Chang KO
Sci Transl Med; 2020 Aug; 12(557):. PubMed ID: 32747425
[TBL] [Abstract][Full Text] [Related]
20. Uncovering Flexible Active Site Conformations of SARS-CoV-2 3CL Proteases through Protease Pharmacophore Clusters and COVID-19 Drug Repurposing.
Pathak N; Chen YT; Hsu YC; Hsu NY; Kuo CJ; Tsai HP; Kang JJ; Huang CH; Chang SY; Chang YH; Liang PH; Yang JM
ACS Nano; 2021 Jan; 15(1):857-872. PubMed ID: 33373194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
